Pfizer’s $93M Resolution: Lipitor Antitrust MDL Culminates

Pfizer's $93M Resolution: Lipitor Antitrust MDL Culminates

Pfizer Inc. has plunged into a $93 million pact, quelling the tumultuous waves of litigation in the colossal antitrust multidistrict litigation (MDL) concerning the cholesterol-controlling juggernaut, Lipitor. This momentous development, filed Wednesday in the federal courts of New Jersey, marks a seismic shift in a legal saga spanning over a decade.

Pfizer Reaches $93M Deal With Lipitor Buyers In Antitrust MDL: Allegations and Accord

The accord in question navigates the labyrinth of claims from direct purchasers of Lipitor, including pharmaceutical wholesalers and distributors. These aggrieved entities hurled accusations at Pfizer, alleging a Machiavellian collusion with Ranbaxy Laboratories Ltd. The crux of their contention revolves around a purported scheme to stymie the emergence of a more economical generic version of Lipitor, thus monopolizing the market’s reins.

Pfizer Reaches $93M Deal With Lipitor Buyers In Antitrust MDL: The Settlement Class

Spanning the expanse of the United States and its territories, the settlement class encompasses all entities that directly procured Lipitor or its generic counterparts from Pfizer or its affiliates between the months of June 2011 and May 2012. A consortium of heavyweight attorneys from Berger Montague, Garwin Gerstein & Fisher LLP, and Hagens Berman Sobol Shapiro LLP stand poised to lead the charge, seeking attorney fees of up to a third of the settlement amount.

The Pillars of Representation

Drogueria Betances LLC, Professional Drug Co. Inc., Rochester Drug Co-Operative Inc., Stephen L. LaFrance Holdings Inc., and Value Drug Co. stand as the named plaintiffs, spearheading the interests of the settlement class as class representatives.

Pfizer’s Stance and Settlement

In a defiant retort, Pfizer reiterated its steadfast stance, vehemently refuting any semblance of liability or wrongdoing. Nonetheless, the arduous odyssey of litigation, extending over a tumultuous 12 years, compelled Pfizer to discern the proposed class settlement as a beacon of resolution. Under the terms of the agreement, Pfizer’s concession does not translate into an admission of culpability.

Pfizer Reaches $93M Deal With Lipitor Buyers In Antitrust MDL: The Nexus of Litigation

Central to the MDL’s crucible lies an intricate agreement forged between Pfizer and Ranbaxy, ostensibly resolving disputes over patent infringement. However, the plaintiffs contend that this covenant, veiled in legality, orchestrated a chilling effect on market competition, thwarting the ingress of a generic challenger.

Echoes of Justice

Despite the resounding echoes of this historic settlement, voices from the plaintiffs’ legal camp remained veiled in silence, declining to provide immediate commentary.

The Legal Legion

A formidable battalion of legal luminaries stands fortified on either side of this legal battleground. Counsel for the direct purchasers, hailing from an array of prestigious firms, braces to etch their mark on the annals of legal history. Meanwhile, Pfizer’s defense finds its vanguard in the adept representation of Walsh Pizzi O’Reilly Falanga LLP and White & Case LLP.


The saga of the Lipitor Antitrust Litigation, encapsulated within the precincts of case number 3:12-cv-02389, now nestles within the annals of the U.S. District Court for the District of New Jersey, a testament to the relentless pursuit of justice amidst the labyrinthine corridors of commerce and law.